Comparing outcomes for all available monoclonal antibody treatments for COVID, this study found the risk for hospitalization or death at 28 days was 4.6% in treated patients and 7.6% in nontreated control patients. Relative risk was somewhat lower for Alpha and Delta variants, and highest for Omicron variants.